Opinion

Video

BOND-003 Trial and Cretostimogene for Treatment of NMIBC

Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune stimulation via granulocyte-macrophage colony-stimulating factor expression.

Video Player is loading.
Current Time 0:00
Duration 8:00
Loaded: 0%
Stream Type LIVE
Remaining Time 8:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is prompted by the following:

    • What is cretostimogene grenadenorepvec? Please describe its mechanism of action.
    • Discuss the phase 3 BOND-003 clinical trial investigating the use of the intravesical immunotherapy cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive disease that was recently presented at the Society of Urologic Oncology 2024.
    • What are your impressions of the BOND-003 data?
    © 2025 MJH Life Sciences

    All rights reserved.